KRAZATI ® (adagrasib), FDA Approved for Treatment of Advanced Non-Small Cell Lung Cancer Harboring the KRASG12C Mutation, Available at Biologics by McKesson
CARY, N.C., Dec. 14, 2022 — Biologics by McKesson, an independent specialty pharmacy focused on oncology and rare disease areas, has been selected by Mirati therapeutics as one of two specialty pharmacies in a limited distribution network for KRAZATI® (adagrasib), which is indicated for the treatmen... (Source: McKesson News)
Source: McKesson News - December 14, 2022 Category: Information Technology Source Type: news
Dedicated care team guides patient through lung cancer with latest treatment
On the same December day in 2016, Patty Jones celebrated the birth of her ninth grandchild and learned she had advanced non-small cell lung cancer. “I knew I had to get this cancer behind me because I had another grandchild to watch grow up and graduate from school,” said Jones, who credits her family, God and the care she received at Atrium Health Wake Forest Baptist’s Comprehensive Cancer Center for saving her life.
“God opened all t he doors for me to be introduced to the Comprehensive… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 14, 2022 Category: American Health Authors: Atrium Health Wake Forest Baptist Source Type: news
Adagrasib (Krazati) Approved for KRAS-Mutated NSCLC Adagrasib (Krazati) Approved for KRAS-Mutated NSCLC
It becomes the second KRAS-targeted therapy for use in patients with non –small cell lung cancer (NSCLC) whose tumors have this mutation.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 13, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
FDA Approves Krazati (adagrasib) for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
SAN DIEGO, Dec. 12, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 12, 2022 Category: Drugs & Pharmacology Source Type: news
Liquid Biopsies in NSCLC May Prolong Patients' Lives Liquid Biopsies in NSCLC May Prolong Patients' Lives
Patients with ctDNA alterations who received targeted therapy on the basis of these alterations survived longer than patients who did not receive targeted therapy. (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
3 Top Stocks to Buy Hand Over Fist Before the End of 2022
You don't have to be in a hurry when it comes to buying stocks. At least that's true most of the time. Whether you invest sooner or later usually doesn't matter all that much over the long run. However, there are some examples where a sense of urgency could be appropriate to some extent. Here are…#elilillyelililly #lly #nsclc #occidental #oxy #ttfields #cms #occidentalpetroleum #berkshirehathaway #novocure (Source: Reuters: Health)
Source: Reuters: Health - December 12, 2022 Category: Consumer Health News Source Type: news
In Early-Stage NSCLC, Give Nivolumab Before or After Surgery? In Early-Stage NSCLC, Give Nivolumab Before or After Surgery?
Dr Mark Kris discusses the choice between neoadjuvant and adjuvant nivolumab for patients with early-stage lung cancer.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 9, 2022 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
Where Are Checkpoint Inhibitors Standard of Care for NSCLC? Where Are Checkpoint Inhibitors Standard of Care for NSCLC?
Dr Mark Kris discusses the use of checkpoint inhibitors in the adjuvant and neoadjuvant settings for patients with non-small cell lung cancer.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 9, 2022 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
More Frequent Scans Not Linked to Improved Survival After Lung Cancer Surgery
More frequent surveillance not linked to longer recurrence - free, overall survival in pathologic stage I non - small cell lung cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 7, 2022 Category: Cancer & Oncology Tags: Oncology, Pulmonology, Radiology, Surgery, Journal, Source Type: news
More Frequent Scans Not Linked to Improved Survival After Lung Cancer Surgery
WEDNESDAY, Dec. 7, 2022 -- For veterans with pathologic stage I non-small cell lung cancer receiving surgery, more frequent surveillance after surgery is not associated with improved survival, according to a study published online Nov. 29 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 7, 2022 Category: Pharmaceuticals Source Type: news
ICIs With Chemotherapy or Anti-Angiogenics for NSCLC ICIs With Chemotherapy or Anti-Angiogenics for NSCLC
Is immune checkpoint inhibitor combination therapy a safe and effective second-line treatment option for advanced non-small cell lung cancer patients?Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 7, 2022 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody
$500 Million Upfront Payment to Activate the Partnership for Ivonescimab Menlo Park, California, US, and Grand Cayman, Cayman Islands, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced a definitive agreement of its…#summitsboardofdirectors #privatesecuritieslitigationreformact #maturitydates #cambridge #nsclc #februarymaturitydate #mainboardofstockexchange #summitscommonstock #riskfactors #securitiesandexchangecommission (Source: Reuters: Health)
Source: Reuters: Health - December 6, 2022 Category: Consumer Health News Source Type: news
Advances in Non-Small Cell Lung Cancer From SITC 2022 Advances in Non-Small Cell Lung Cancer From SITC 2022
The role of gene mutations in outcomes and treatment resistance, a novel LAG-3 inhibitor, and the case for neoadjuvant therapy are among the NSCLC highlights from SITC 2022 reported by Dr Jack West.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 6, 2022 Category: Consumer Health News Tags: None ReCAP Source Type: news
Phase III results show Roche's subcutaneous formulation of Tecentriq is comparable to intravenous Tecentriq and delivered in minutes
Administered under the skin, the subcutaneous formulation reduces time spent receiving treatment to approx. seven minutes, compared with 30-60 minutes for IV infusion1Roche has submitted data from the IMscin001 study to health authorities, seeking approval for the subcutaneous option across all approved indications of IVTecentriq If approved,Tecentriq would be Roche ’s fourth subcutaneous cancer therapy,2-4 helping to improve the treatment experience for patients. In addition, it could save resources for healthcare systems5-10Basel, 1 December 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new pivotal data ...
Source: Roche Investor Update - December 1, 2022 Category: Pharmaceuticals Source Type: news
FDA Rejects Poziotinib for Certain Types of NSCLC FDA Rejects Poziotinib for Certain Types of NSCLC
The drug was not approved for the treatment of patients with previously treated locally advanced or metastatic nonsmall cell lung cancer harboring HER2 exon 20 insertion mutations.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 25, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
